GlassScriptPhysician profile
Diem Chieu Chang
NPI 1730335951
$4,691.32
in general payments reported to CMS, 2019-2025
27 companies · $584 in 2025
The $584 reported for 2025 was more than what 92% of General Practice (Dentist) providers received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $385 · 2021: $1,015 · 2022: $846 · 2023: $622 · 2024: $891 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,186.12 | 2020-2025 | Krystexxa, Repatha |
| Novo Nordisk INC | $635.75 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $548.37 | 2021-2022 | |
| Esperion Therapeutics, INC. | $300.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.78 | 2022 | |
| Dexcom, INC. | $198.89 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $177.01 | 2021-2023 | |
| Embecta Corp. | $161.24 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $150.96 | 2025 | |
| Cequr Corporation | $149.23 | 2023 | Cequr Simplicity |
| Abbott Laboratories | $145.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.13 | 2022 | |
| Amarin Pharma, INC. | $123.66 | 2020 | |
| Alexion Pharmaceuticals, INC. | $109.78 | 2019-2022 | |
| Mannkind Corporation | $75.94 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $65.89 | 2019-2020 | |
| Genentech USA, INC. | $56.90 | 2021-2023 | Xolair |
| Astrazeneca Pharmaceuticals LP | $35.05 | 2019-2023 | Farxiga |
| Premier Dental Products Company | $35.00 | 2019 | |
| Acerus Pharmaceuticals Corporation | $26.25 | 2020 | |
| Alvogen INC | $25.35 | 2023 | Teriparatide |
| Exeltis, USA INC. | $23.17 | 2023 | Slynd |
| Pfizer INC. | $21.03 | 2025 | |
| Merck Sharp & Dohme LLC | $17.63 | 2022 | |
| Calliditas Therapeutics US INC. | $17.02 | 2025 | Tarpeyo |
| Amryt Pharma Holdings LTD | $16.80 | 2023 | Mycapssa |
| Antares Pharma, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diem Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.